Piper Sandler lowered the firm’s price target on PacBio (PACB) to $2 from $2.50 following quarterly results. The firm keeps a Neutral rating on the shares.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Unusually active option classes on open February 18th
- Largest borrow rate increases among liquid names
- Pacific Biosciences: Hold Rating Amid Revenue Guidance Challenges and Positive Vega System Prospects
- PacBio grants equity incentive award to new employee
- PacBio’s 2024 Earnings: Growth Amid Challenges